治疗结果的分析婴儿发作综合征的治疗结果的变化
Xue Gong1,2, Jing Gan1,3, Xiaoqian Wang1
1Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China.
Frontiers in neurology
|March 5, 2026
概括
婴儿发作综合征 (IESS) 治疗结果取决于病因. 遗传原因导致对ACTH等疗法的反应较差,但组合治疗可能有所帮助. 了解这些因素可以优化IESS的临床实践.
科学领域:
- 儿科神经学 儿科神经学
- 临床遗传学 临床遗传学
- 发病学 (Epileptology) 是一个专业的学科.
背景情况:
- 婴儿发作综合征 (IESS) 在儿科神经学中是一个重大挑战.
- 确定影响IESS结果的关键因素对于完善治疗策略至关重要.
- 了解病因和治疗反应之间的相互关系对于优化临床实践至关重要.
研究的目的:
- 调查影响IESS诊断儿童结果的主要因素.
- 分析遗传和非遗传病因与治疗疗效之间的相互关系.
- 为改善IESS的临床管理提供基于证据的见解.
主要方法:
- 对128名患有IESS的儿童进行了回顾性单中心研究 (2019年4月至2024年4月).
- 评估遗传和非遗传病因子组 (结构性与未知原因).
- 基因检测结果的比较,相关性和治疗疗效和风险因素的后勤回归分析.
主要成果:
- 基因阳性IESS病例显示早期发病,低血压和发育回归.
- 基因阴性病例中的结构异常与更频繁的EEG高节律症有关.
- 基因阳性组对ACTH和vigabatrin的反应较差;组合治疗显示出有前途. 非ACTH治疗产生了更好的EEG改善 (p=0.028).
- 治疗反应率为75% (基因阳性) 和100% (基因阴性). 频繁的发作和发育衰退是基因阴性病例中反应不良的危险因素.
结论:
- IESS的预后与病因密切相关,遗传因素与对标准疗法的反应减弱有关.
- 与ACTH和维加巴林的联合治疗可能会改善选择IESS患者的结果.
- 治疗ACTH可能不会显著影响IESS的长期EEG结果,这表明需要以病因学为导向的治疗方法.
相关概念视频
01:29Spasmolytic Agents: Chemical Classification
1.4K
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.4K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.0K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K